サポート>ブログ>モノクローナル抗体の使用における利点と欠点

モノクローナル抗体の使用における利点と欠点

Biointron 2024-01-20
MAbs.jpg
Image credit: The Wellcome Trust

Monoclonal antibodies (mAbs) are immunoglobulins obtained from single cloned homogeneous hybrid cells (B lymphocyte cells). This is done by fusing spleen cells of an antigen-exposed mouse with human or mouse myeloma cells, then cloning the hybridomas to produce the desired single antibody clone. 

They are used for diagnosis and treatment in various therapeutic areas, including cancer, infectious viral, and bacterial diseases. mAbs can bind to pathogens to reduce their capability to infect new cells, or bind to receptors of microbes, abnormal cells, and proteins, thus preventing escalation of the disease-state and subsequent infections.1 However, mAbs have several pros and cons when being considered for research. 

Pros 

  • Binds with high specificity due to being products of a single clone, and most mAbs do not show cross-reactivity. 

  • Multiple uses (incl. diagnostic assays, therapies) and treats a wide range of conditions. 

  • Hybridoma cells which produce mAbs are perpetual sources of antibodies with the same specificity and sensitivity. 

  • Can be used with or without purification. 

  • Very useful for conjugation to different probes as their homogenous chemical nature can be characterized easily. 

  • Side effects of mAb drugs can be treated through optimization, such as humanization or affinity maturation, or by using antibody fractions.

Cons 

  • More expensive than polyclonal antibodies. 

  • Production requires both in vivo and in vitro systems due to laborious process of producing immortalized hybridoma cell lines. 

  • Skilled and trained workers are essential. 

  • Potential adverse effects when used in therapeutics if human anti-monoclonal antibody (HAMA) response is triggered. 

  • Due to its homogeneity, mAbs are vulnerable to degradation because of the shared susceptibility among all antibody molecules within the solution. 

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


References: 

  1. Singh, A., Chaudhary, S., Agarwal, A., & Verma, A. S. (2014). Antibodies: Monoclonal and Polyclonal. Animal Biotechnology, 265-287. https://doi.org/10.1016/B978-0-12-416002-6.00015-8 

Subscribe to our ブログ
Recommended Articles
人間の免疫システムの活用:自然な防御から精密医療へ

免疫・PAMP/DAMP・革新的抗体療法の解説

Aug 08, 2025
抗体薬物複合体(ADC)の基礎レビュー:作用機序、臨床進展、設計最適化、課題、および将来

抗体薬物複合体(Antibody-Drug Conjugates, ADC)は、がん治療において革新的なターゲット型治療薬の一つであり、モノクローナル抗体(mA……

Aug 05, 2025
抗体機能におけるFc糖鎖の役割

抗体の機能は、Fc領域の糖鎖修飾状態に大きく依存しています。

Jun 25, 2025
AIS 2025 – フランス:ハイライトとイベント総括

第13回抗体産業シンポジウム(Antibody Industrial Symposium 2025)が、2025年6月25日から26日にかけてフランス・トゥール……

Jun 22, 2025

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。